Medical Research: What are the main findings of the study?
Dr. Sanlorenzo: In the treatment of BRAF mutant melanoma, the combination of BRAF inhibitor and MEK inhibitor has a better cutaneous safety profile compared with BRAF inhibitor monotherapy. Combination regimen shows fewer cutaneous adverse events and longer cutaneous adverse event-free interval. In particular, the development of squamous cell carcinoma or keratoacanthoma was significantly less frequent.
Medical Research: What was most surprising about the results?
Dr. Sanlorenzo: BRAF and MEK inhibitor combination therapy, which previously showed improved progression-free survival over single inhibitor therapy, is also related to a better cutaneous safety profile.
Regardless of the treatment regimen, anytime a patient receives vemurafenib, particular attention should be given to sun-exposure prevention measures.
Medical Research: What should clinicians and patients take away from your report?
Dr. Sanlorenzo: Each inhibitor and each combination has a particular cutaneous safety profile. Knowledge of expected cutaneous adverse events can help clinical decision- making during follow-up.
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
Sanlorenzo, Martina et al.
Journal of the American Academy of Dermatology
JAAD September 2, 2014; Published Online: October 15, 2014